Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma <i>a multicenter propensity matching analysis</i>.

Front Immunol · 2023 · PMC10806403 · PMID 38268916

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

While patients with intermediate-stage HCC was associated with a positive trend toward improved RFS and OS, patients with advanced-stage HCC derived the most benefit from ICI adjuvant therapy.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.